NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QELBREE (viloxazine HCl) is an oral extended-release capsule approved in 2021 for the treatment of ADHD in pediatric and adult patients. It is a selective norepinephrine reuptake inhibitor (NRI) that modulates noradrenergic neurotransmission to improve attention and executive function.
$0.004BPart D
Peak8.9 years to LOEEarly-peak ADHD product with modest Medicare utilization; commercial team likely focused on expansion into commercial/pediatric channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QELBREE currently shows minimal direct job posting volume, likely reflecting its niche position and Supernus' smaller commercial footprint compared to major competitors. Career opportunities exist in brand management, medical affairs, and field sales roles at Supernus.
Company
Worked on QELBREE at Supernus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.